Lumida
/CTMX
⌘K
CytomX Therapeutics Inc

CytomX Therapeutics Inc

CTMX
$3.29USD-1.79%-0.06 today

MARKET CAP

716.9M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$8

AI Summary

Stalk
Buy NowMedium

CTMX is showing early Stage 1 repair after the mid-June low, confirmed by a Bullish Pivot Point pattern and stacked short-term EMAs; medium-term bias shifts bullish, and execution on holds above the EMA9/20 support is warranted.

  • ORR of 28% and median PFS of 7.1 months in colorectal cancer
  • $346.7M cash as of Q1 2026 underpins R&D runway through 2027
  • Q1 2026 revenue dropped 80% to $10.3M from $50.9M YoY
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$37.3M$53.2M$101.2M$138.1M$76.2M
YoY %-45.5%+42.5%+90.4%+36.4%-44.8%
P / Sales7.4x2.0x1.2x0.6x7.7x
EV / Sales11.0x4.9x3.5x1.2x8.2x
Gross Profit, Adj.$37.3M$53.2M$101.2M$138.1M$76.2M
YoY %-45.5%+42.5%+90.4%+36.4%-44.8%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit11.0x4.9x3.5x1.2x8.2x
EBITDA, Adj.$-116.0M$-98.9M$-4.3M$26.8M$-21.0M
YoY %-48.8%+14.8%+95.6%+721.1%-178.4%
Margin %-311.0%-186.0%-4.3%19.4%-27.5%
EV / EBITDA-3.6x-2.6x-82.8x6.4x-29.9x
EBIT$-116.0M$-101.3M$-6.5M$25.0M$-22.4M
YoY %-44.1%+12.7%+93.6%+485.5%-189.5%
Margin %-311.0%-190.6%-6.4%18.1%-29.3%
EV / EBIT-3.6x-2.6x-55.0x6.8x-28.1x
Net Income$-115.9M$-99.3M$-569,000$31.9M$-20.4M
YoY %-78.8%+14.3%+99.4%+5700.9%-163.9%
Net Margin-310.5%-186.8%-0.6%23.1%-26.7%
EPS (GAAP)-$1.81-$1.51-$0.01$0.38-$0.15
YoY %-29.3%+16.6%+99.3%+3900.0%-139.5%